These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 27933890)

  • 1. Discovery of Leucyladenylate Sulfamates as Novel Leucyl-tRNA Synthetase (LRS)-Targeted Mammalian Target of Rapamycin Complex 1 (mTORC1) Inhibitors.
    Yoon S; Kim JH; Kim SE; Kim C; Tran PT; Ann J; Koh Y; Jang J; Kim S; Moon HS; Kim WK; Lee S; Lee J; Kim S; Lee J
    J Med Chem; 2016 Nov; 59(22):10322-10328. PubMed ID: 27933890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel leucyladenylate sulfamate surrogates as leucyl-tRNA synthetase (LRS)-targeted mammalian target of rapamycin complex 1 (mTORC1) inhibitors.
    Yoon S; Zuo D; Kim JH; Yoon I; Ann J; Kim SE; Cho D; Kim WK; Lee S; Lee J; Kim S; Lee J
    Bioorg Med Chem; 2018 Aug; 26(14):4073-4079. PubMed ID: 30041947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationship of leucyladenylate sulfamate analogues as leucyl-tRNA synthetase (LRS)-targeting inhibitors of Mammalian target of rapamycin complex 1 (mTORC1).
    Yoon S; Kim SE; Kim JH; Yoon I; Tran PT; Ann J; Kim C; Byun WS; Lee S; Kim S; Lee J; Lee J
    Bioorg Med Chem; 2019 Mar; 27(6):1099-1109. PubMed ID: 30755350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of simplified leucyladenylate sulfamates as novel leucyl-tRNA synthetase (LRS)-targeted mammalian target of rapamycin complex 1 (mTORC1) inhibitors.
    Yoon S; Kim JH; Koh Y; Tran PT; Ann J; Yoon I; Jang J; Kim WK; Lee S; Lee J; Kim S; Lee J
    Bioorg Med Chem; 2017 Aug; 25(15):4145-4152. PubMed ID: 28625715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of (S)-4-isobutyloxazolidin-2-one as a novel leucyl-tRNA synthetase (LRS)-targeted mTORC1 inhibitor.
    Yoon S; Kim JH; Yoon I; Kim C; Kim SE; Koh Y; Jeong SJ; Lee J; Kim S; Lee J
    Bioorg Med Chem Lett; 2016 Jul; 26(13):3038-3041. PubMed ID: 27209231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of leucine-dependent mTORC1 pathway through chemical intervention of leucyl-tRNA synthetase and RagD interaction.
    Kim JH; Lee C; Lee M; Wang H; Kim K; Park SJ; Yoon I; Jang J; Zhao H; Kim HK; Kwon NH; Jeong SJ; Yoo HC; Kim JH; Yang JS; Lee MY; Lee CW; Yun J; Oh SJ; Kang JS; Martinis SA; Hwang KY; Guo M; Han G; Han JM; Kim S
    Nat Commun; 2017 Sep; 8(1):732. PubMed ID: 28963468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based modification of pyrazolone derivatives to inhibit mTORC1 by targeting the leucyl-tRNA synthetase-RagD interaction.
    Kim JH; Jung K; Lee C; Song D; Kim K; Yoo HC; Park SJ; Kang JS; Lee KR; Kim S; Han JM; Han G
    Bioorg Chem; 2021 Jul; 112():104907. PubMed ID: 33979735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leucine-induced localization of Leucyl-tRNA synthetase in lysosome membrane.
    Choi H; Son JB; Kang J; Kwon J; Kim JH; Jung M; Kim SK; Kim S; Mun JY
    Biochem Biophys Res Commun; 2017 Nov; 493(2):1129-1135. PubMed ID: 28882589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coordination of the leucine-sensing Rag GTPase cycle by leucyl-tRNA synthetase in the mTORC1 signaling pathway.
    Lee M; Kim JH; Yoon I; Lee C; Fallahi Sichani M; Kang JS; Kang J; Guo M; Lee KY; Han G; Kim S; Han JM
    Proc Natl Acad Sci U S A; 2018 Jun; 115(23):E5279-E5288. PubMed ID: 29784813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leucyl-tRNA synthetase is an intracellular leucine sensor for the mTORC1-signaling pathway.
    Han JM; Jeong SJ; Park MC; Kim G; Kwon NH; Kim HK; Ha SH; Ryu SH; Kim S
    Cell; 2012 Apr; 149(2):410-24. PubMed ID: 22424946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leucyl-tRNA synthetase: double duty in amino acid sensing.
    Durán RV; Hall MN
    Cell Res; 2012 Aug; 22(8):1207-9. PubMed ID: 22525334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acidic tumor microenvironment abrogates the efficacy of mTORC1 inhibitors.
    Faes S; Duval AP; Planche A; Uldry E; Santoro T; Pythoud C; Stehle JC; Horlbeck J; Letovanec I; Riggi N; Demartines N; Dormond O
    Mol Cancer; 2016 Dec; 15(1):78. PubMed ID: 27919264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTORC1-Driven Tumor Cells Are Highly Sensitive to Therapeutic Targeting by Antagonists of Oxidative Stress.
    Li J; Shin S; Sun Y; Yoon SO; Li C; Zhang E; Yu J; Zhang J; Blenis J
    Cancer Res; 2016 Aug; 76(16):4816-27. PubMed ID: 27197195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leucyl-tRNA Synthetase Activates Vps34 in Amino Acid-Sensing mTORC1 Signaling.
    Yoon MS; Son K; Arauz E; Han JM; Kim S; Chen J
    Cell Rep; 2016 Aug; 16(6):1510-1517. PubMed ID: 27477288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzofuran derivatives as anticancer inhibitors of mTOR signaling.
    Salomé C; Ribeiro N; Chavagnan T; Thuaud F; Serova M; de Gramont A; Faivre S; Raymond E; Désaubry L
    Eur J Med Chem; 2014 Jun; 81():181-91. PubMed ID: 24836070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTORC1 is a target of nordihydroguaiaretic acid to prevent breast tumor growth in vitro and in vivo.
    Zhang Y; Xu S; Lin J; Yao G; Han Z; Liang B; Zou Z; Chen Z; Song Q; Dai Y; Gao T; Liu A; Bai X
    Breast Cancer Res Treat; 2012 Nov; 136(2):379-88. PubMed ID: 23053656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relations of leucine derivatives reveal critical moieties for cellular uptake and activation of mTORC1-mediated signaling.
    Nagamori S; Wiriyasermkul P; Okuda S; Kojima N; Hari Y; Kiyonaka S; Mori Y; Tominaga H; Ohgaki R; Kanai Y
    Amino Acids; 2016 Apr; 48(4):1045-1058. PubMed ID: 26724922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel leucine ureido derivatives as aminopeptidase N inhibitors. Design, synthesis and activity evaluation.
    Ma C; Cao J; Liang X; Huang Y; Wu P; Li Y; Xu W; Zhang Y
    Eur J Med Chem; 2016 Jan; 108():21-27. PubMed ID: 26629857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells.
    Teo T; Yu M; Yang Y; Gillam T; Lam F; Sykes MJ; Wang S
    Cancer Lett; 2015 Feb; 357(2):612-23. PubMed ID: 25527453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anti-hepatocellular carcinoma cell activity by a novel mTOR kinase inhibitor CZ415.
    Zhang W; Chen B; Zhang Y; Li K; Hao K; Jiang L; Wang Y; Mou X; Xu X; Wang Z
    Biochem Biophys Res Commun; 2017 Jun; 487(3):494-499. PubMed ID: 28366631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.